Publications, Pharmaceutical

Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2

The delivery of antibodies by nasal spray has considerable potential for the treatment of SARS-CoV-2 and other viruses that enter the body via the upper respiratory system.

This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.

Download Publication
8 Dec 2021

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

8 Sep 2022

Case Study – Bidose Nasal Spray Pump for Depression

Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
8 Sep 2022

Case Study – Unidose Nasal Spray Pump in Hypoglycemia

Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
8 Sep 2022

Case Study – Unidose Nasal Spray Pump for Opioid Overdose

Case Studies, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
1 Sep 2022

Spray Dried Formulations for Nasal Applications – Challenges an...

Publications, Pharmaceutical, Device Innovations, Product Solutions

Read More
1 2 3 16
Back To Top